Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Trial Profile

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs LU AA34893 (Primary) ; Quetiapine
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2012 Actual initiation date (28 Nov 2007) added as reported by European Clinical Trials Database record.
    • 24 Sep 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top